The inhibitor of integrins cilengitide: A new active drug in neuro-oncology;L'inhibiteur d'intégrines cilengitide: Un nouveau principe actif en neuro-oncologie

Bulletin du Cancer

Volumn 98, Issue 9, 2011, Pages 1083-1090

  Leblond, Pierre ^a   Meignan, Samuel ^b   Le Tinier, Florence ^b   Bethe, Ullrich ^c   Lansiaux, Ameĺie ^b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c MERCK KGAA   (Germany)

Author keywords

Angiogenesis; Cilengitide; Integrins; Neuro oncology; Targeted therapies

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTYLSERINE; CILENGITIDE;

BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; DRUG MECHANISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; IN VITRO STUDY; IONIZING RADIATION; NEUROLOGY; ONCOLOGY; REVIEW; TUMOR CELL;

EID: 80053482090     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1429     Document Type: Review

References (38)

1. Pouessel D, Culine S. Angiogenesis targeting in renal carcinomas. Bull Cancer 2007; 94 : F223-6. (Pubitemid 350131948)
2. Lartigau E. Angiogenèse et radiothérapie (vaisseaux, anémie, oxygène et radiosensibilité). Bull Cancer 2007; 94 : S197-202.
3. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15 : 232-9.
4. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15 : 220-31.
5. Takada Y, Ye X, Simon S. The integrins. Genome Biol2007; 8 : 215.
6. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110 : 673-87. (Pubitemid 35283958)
7. Hynes RO, Lively JC, McCarty JH, et al. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol 2002; 67 : 143-53. (Pubitemid 36775506)
8. Huveneers S, Truong H, Danen HJ. Integrins: signaling, disease, and therapy. Int J Radiat Biol 2007; 83 : 743-51. (Pubitemid 350219110)
9. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223 : 14-26.
10. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10 : 9-22.
11. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin anb3 for angiogenesis. Science 1994; 264 : 569-71. (Pubitemid 24185862)
12. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct an integrins. Science 1995; 270 : 1500-2. (Pubitemid 3005294)
13. Friedlander M, Theesfeld CL, Sugita M, et al. Involvment of integrins anb3 and anb5 in ocular neovascular diseases. Proc Natl Acad Sci 1996; 93 : 9764-9.
14. Bellail AC, Hunter SB, Brat DJ, Tan C, van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004; 36 : 1046-69. (Pubitemid 38501557)
15. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991; 88 : 1924-32.
16. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 1995; 108 : 947-56.
17. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009; 15 : 1163-9.
18. Oliveira-Ferrer L, Hauschild J, Fiedler W, et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008; 27 : 86.
19. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124 : 2719-27.
20. Dechantsreiter MA, Planker E, Mathä B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42 : 3033-40. (Pubitemid 29384038)
21. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6 : 105-19. (Pubitemid 38173862)
22. Taga T, Suzuki A, Gonzalez-Gomez I, et al. an-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98 : 690-7. (Pubitemid 34228889)
23. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009; 11 : 747-56.
24. Loges S, Butzal M, Otten J, et al. Cilengitide inhibits proliferation and differenciation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 2007; 357 : 1016-20. (Pubitemid 46695889)
25. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46 : 135-44. (Pubitemid 30352620)
26. Yamada S, Bu XY, Khankaldyvan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006; 59 : 1304-12. (Pubitemid 44949775)
27. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha (v) integrin antagonist. Neurosurgery 2001; 48 : 151-7. (Pubitemid 32039837)
28. Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11 : 6270-9. (Pubitemid 41262958)
29. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006; 65 : 1536-43. (Pubitemid 44425239)
30. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62 : 4263-72. (Pubitemid 34827281)
31. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39 : 917-26. (Pubitemid 36428623)
32. Hariharan S, Gustafson D, Holden S, et al. Assessment of the biological and pharmacological effects of the anb3 and anb5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007; 18 : 1400-7. (Pubitemid 47305015)
33. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25 : 1651-7. (Pubitemid 46797943)
34. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastome multiforme. J Clin Oncol 2008; 26 : 5610-7.
35. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008; 26 : 919-24. (Pubitemid 351398085)
36. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007; 25 : 1637-8. (Pubitemid 46797938)
37. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 : 987-96. (Pubitemid 40349501)
38. Nabors LB, Mikkelsen T, Batchelor T, et al. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). ASCO Meeting Abstracts 2009; 27 : 2001.